Two studies reveal new therapeutic approaches for lung cancer patients with BRAFV600E and KRASG12C mutations. The advanced preclinical models generated by IDIBELL and ICO professionals have been essential for this research.
This new study, based on 1,886 women with sleep apnea, reveals a heterogeneous presentation of the pathology in women similar to that of men, contrary to previous literature that often associated women with a predominantly atypical presentation.
UMBRELLA addresses the stroke care process from diagnosis, prevention, episode care and rehabilitation.
IDIBELL participates in the European project UMBRELLA Read More »
The Stanford University Top 2% of Scientists, which includes the most impactful scientists of the world, includes this year 34 IDIBELL researchers, of which three reaffirm their position among the top 10 in Spain and four have first entered.
The Northwestern University (Chicago), IDIBELL and IBEC were awarded a NIH project that will help develop new treatments for spinal cord injuries and other neurodegenerative pathologies.
Pablo Naval, Laura Costas, Josep M. Aran and Antonella Consiglio will develop their research and innovation projects within the framework of this call.
Four IDIBELL researchers receive funding from the CaixaImpulse 2024 call Read More »
More studies would open new paths contributing to the prevention of gastrointestinal conditions such as colorectal cancer or inflammatory bowel diseases through diet.
Foods such as oily fish or potatoes influence gene expression in the colon Read More »
Paula Jakszyn (IDIBELL & ICO) and Dr. Jordi Vilaró (URL) team has been chosen to develop a serious game that promotes physical activity in patients with chronic pathologies.
B-ACTIVE: serious games platform to promote healthy behavior in people with cancer Read More »
IDIBELL, HUB and ICO have led a European study that presents an innovative tool to assess chemotherapy-induced peripheral neuropathy (CIPN). The great advantage of this system is that it incorporates the patient’s perception, an aspect that until now medical scales did not adequately take into account.
The CUPISCO study, the largest to date on cancer of unknown primary, reveals that molecularly guided therapy is more effective than standard chemotherapy in cancer cases with an unfavorable prognosis.
